ImmuneWalk Therapeutics Announces Positive Results from Phase I SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Autoimmune Diseases

ImmuneWalk Therapeutics announced positive results from the POINTGUARD study evaluating subcutaneously administered IW-601, a highly selective biologic inhibitor of myeloid cell tissue infiltration. The study met all primary and secondary endpoints, demonstrating safety and tolerability of IW-601 at all doses.